WO2002078613A3 - Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response - Google Patents

Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response Download PDF

Info

Publication number
WO2002078613A3
WO2002078613A3 PCT/US2002/010304 US0210304W WO02078613A3 WO 2002078613 A3 WO2002078613 A3 WO 2002078613A3 US 0210304 W US0210304 W US 0210304W WO 02078613 A3 WO02078613 A3 WO 02078613A3
Authority
WO
WIPO (PCT)
Prior art keywords
variable domain
mucin
eliciting
idiotype
domain sequences
Prior art date
Application number
PCT/US2002/010304
Other languages
French (fr)
Other versions
WO2002078613A2 (en
Inventor
Daniel A Soltis
Ronald M Burch
Rajiv Shukla
Original Assignee
Purdue Pharma Lp
Daniel A Soltis
Ronald M Burch
Rajiv Shukla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp, Daniel A Soltis, Ronald M Burch, Rajiv Shukla filed Critical Purdue Pharma Lp
Priority to AU2002307064A priority Critical patent/AU2002307064A1/en
Priority to US10/469,125 priority patent/US20040143101A1/en
Publication of WO2002078613A2 publication Critical patent/WO2002078613A2/en
Publication of WO2002078613A3 publication Critical patent/WO2002078613A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides a variant of an immunoglobulin variable domain including (A) at least one CDR region and (B) framework regions flanking the CDR region, wherein the variant also contains (a) a CDR region having added or substituted therein at least on binding sequence and (b) the flanking framework regions, wherein the binding sequence is heterelogous to the CDR and is an antigenic sequence from a MUC-1 binding sequence.
PCT/US2002/010304 2001-04-02 2002-04-02 Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response WO2002078613A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002307064A AU2002307064A1 (en) 2001-04-02 2002-04-02 Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
US10/469,125 US20040143101A1 (en) 2001-04-02 2002-04-02 Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28118201P 2001-04-02 2001-04-02
US60/281,182 2001-04-02

Publications (2)

Publication Number Publication Date
WO2002078613A2 WO2002078613A2 (en) 2002-10-10
WO2002078613A3 true WO2002078613A3 (en) 2004-02-19

Family

ID=23076282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/010304 WO2002078613A2 (en) 2001-04-02 2002-04-02 Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response

Country Status (3)

Country Link
US (1) US20040143101A1 (en)
AU (1) AU2002307064A1 (en)
WO (1) WO2002078613A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021595A1 (en) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
US20060047434A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to improving an immune system
US20060047435A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to augmenting an immune system
US20060182742A1 (en) * 2004-08-24 2006-08-17 Ishikawa Muriel Y System and method for magnifying a humoral immune response
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
US20060047433A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to enhancing an immune system
US20060116824A1 (en) * 2004-12-01 2006-06-01 Ishikawa Muriel Y System and method for modulating a humoral immune response
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20060047436A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for magnifying an immune response
US20060047437A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for heightening an immune response
US20070265818A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for heightening cell-mediated immune response
US20070265819A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for improving cell-mediated immune response
US20060047439A1 (en) * 2004-08-24 2006-03-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for improving a humoral immune response
US20070198196A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to ameliorating an immune system
US20070196362A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to bolster an immune response
US20070207492A1 (en) * 2004-08-24 2007-09-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to adjust a humoral immune response
WO2012058137A2 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Methods for diversifying antibodies, antibodies derived therefrom and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025379A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Modified antibodies with enhanced ability to elicit an anti-idiotype response
US6204366B1 (en) * 1990-09-07 2001-03-20 Unilever Patent Holdings B.V. Specific binding agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204366B1 (en) * 1990-09-07 2001-03-20 Unilever Patent Holdings B.V. Specific binding agents
WO1999025379A1 (en) * 1997-11-14 1999-05-27 Euro-Celtique, S.A. Modified antibodies with enhanced ability to elicit an anti-idiotype response

Also Published As

Publication number Publication date
AU2002307064A1 (en) 2002-10-15
WO2002078613A2 (en) 2002-10-10
US20040143101A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2002078613A3 (en) Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
WO2003054016A8 (en) Method for cloning of variable domain sequences
WO2002083738A1 (en) Cyclic single strand trispecific antibody
WO2001010380A3 (en) Benzanilides as potassium channel openers
DK1399484T3 (en) Double-specific ligand and its use
WO2003006616A3 (en) Pseudotyped adeno-associated viruses and uses thereof
TR200002921T2 (en) Semi-Synthetic Ekteinacids
WO2001034646A3 (en) Recombinant gelatins
EP1300137A3 (en) Combinations of sunscreens
ZA200204830B (en) Novel method for down-regulation of amyloid.
WO2001010381A3 (en) Methods for treating or preventing pain and anxiety
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
ZA200309471B (en) Method for the preparation of escitalopram.
DK1385826T3 (en) Process for Preparation of (S) - (+) - and (R) - (-) - 10,11-Dihydro-10-hydroxy-5H-dibenz / b, f / azapine-5-carboxamide
WO2000061635A3 (en) Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
ZA200403432B (en) Method for the preparation of escitalopram.
WO2002079474A3 (en) Human b7 polypeptides
WO2005027836A3 (en) Immunogen
AU2002213937A1 (en) Method for modifying the genome of corynebacteria
SI1325022T1 (en) Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op)
NO995348D0 (en) Slide assembly, and method for using it
AU2002221521A1 (en) Immunotherapeutic combinations for the treatment of tumors
NO20013735L (en) Process for the preparation of di-iso-butanes, di-iso-butenes and di-n-butenes from field butanes
WO2001088159A3 (en) Cd28 synthebody for the modulation of immune responses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10469125

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP